| Size | Price | |
|---|---|---|
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Frequently absorbed from the gastrointestinal tract. Peak plasma concentrations occur within 2–4 hours, with an onset of action of 1 hour. Maximum efficacy is achieved 3–6 hours after oral administration of chlorpropamide. 80–90% of a single oral dose is excreted unchanged in the urine within 96 hours as metabolites. …Frequently absorbed from the gastrointestinal tract… Excretion (percentage)…60 /from table/ …20% excreted unchanged;… /from table/ Frequently absorbed from the gastrointestinal tract after oral administration of chlorpropamide. The drug is detectable in plasma within 1 hour after a single oral dose, with peak plasma chlorpropamide concentrations occurring within 2–4 hours. For more complete data on the absorption, distribution, and excretion of chlorpropamides (6 in total), please visit the HSDB record page. Metabolism/Metabolites Up to 80% of the dose may be metabolized in the liver to 2-hydroxychloropropionamide (2-OH CPA), p-chlorobenzenesulfonylurea (CBSU), 3-hydroxychloropropionamide (3-OH CPA), and p-chlorobenzenesulfonamide (CBSA); CBSA may be produced through urinary breakdown. Whether chloropropionamide metabolites have a hypoglycemic effect is unknown. ...Chloropropionamide is not completely metabolized; approximately 20% of the drug is excreted unchanged. ...Partial hydrolysis of urea has been detected, generating sulfonamide derivatives...Recent evidence suggests...this may be an artificial product, not a true metabolite... In one subject, after oral administration of tritium-labeled chloropropionamide...80% of the dose was excreted within 7 days. The metabolite...is p-chlorobenzenesulfonamide...[(p-chlorophenyl)sulfonyl]urea...1-[(p-chlorophenyl)sulfonyl]-3-(2-hydroxypropyl)urea. ...&.1-[(p-chlorophenyl)sulfonyl]-3-(3-hydroxypropyl)urea... ...For diabetic patients.../chloropropionamide/...dosage is...250-500 mg...excretion products...include.../(p-chlorophenyl)sulfonylurea/ (21%).../p-chlorobenzenesulfonamide/ (2%), 2-hydroxychloropropionamide (55%) and 3-hydroxychloropropionamide (2%). For more complete data on the metabolism/metabolites of chloropropionamide (6 in total), please visit the HSDB record page. Known human metabolites of chloropropionamide include p-chlorobenzenesulfonylurea, 2-hydroxychloropropionamide and 3-hydroxychloropropionamide. Biological half-life Approximately 36 hours, with significant individual variability, ranging from 25-60 hours. Duration of action is at least 24 hours. Chloropropionamide has a longer half-life (24 to 48 hours). Half-life...24-48 hours / (Data from table) |
|---|---|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Summary of Use During Lactation Chlorpropamide has been discontinued in the United States. Limited data suggest that chlorpropamide levels in breast milk are unlikely to affect breastfed infants. To avoid drug accumulation, short-acting medications are generally recommended during lactation. Breastfed infants should be monitored for signs of hypoglycemia, such as irritability, lethargy, feeding difficulties, seizures, cyanosis, apnea, or hypothermia. If there is any concern, monitoring of the breastfed infant's blood glucose levels is recommended while the mother is on hypoglycemic medication. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Lactation and Breast Milk No published information found as of the revision date. Protein Binding Highly bound to plasma proteins. Interactions Medications that may increase the risk of hypoglycemia… include other hypoglycemic agents, sulfonamides, propranolol, salicylates, phenylbutazone, probenecid, dicumarol, chloramphenicol, monoamine oxidase inhibitors, and alcohol. /Sulfonylureas/ Allopurinol or its metabolites may compete with chlorpropamide for renal tubular secretion, leading to enhanced chlorpropamide efficacy in a small number of patients. Diphenylam-like reactions may occur when taking any sulfonylurea medication and consuming alcohol concurrently, mainly manifested as facial, neck, and arm flushing… /Sulfonylureas/ The risk of hypoglycemia may increase or its duration may be prolonged when taking sulfonylureas and consuming moderate to large amounts of alcohol concurrently; small amounts of alcohol (after meals) usually do not cause hypoglycemia. /Sulfonylureas/ For more complete data on interactions of chlorpropamides (19 in total), please visit the HSDB record page. Non-human toxicity values Rats oral LD50: 2390 mg/kg Rats intravenous LD50: 590 mg/kg Dogs intravenous LD50: 575 mg/kg Dogs oral LD50: 800 mg/kg Mouse oral LD50: 1680 mg/kg |
| Additional Infomation |
Therapeutic Uses
Hypoglycemic Agents: Sulfonylureas are used to control hyperglycemia in patients with non-insulin-dependent diabetes mellitus (NIDDM) whose blood sugar cannot be effectively controlled by dietary adjustments alone. /Sulfonylureas/ …Effective in adult-onset diabetes patients whose pancreas still has the ability to secrete insulin. /Sulfonylureas/ Veterinary Use: Used to treat canine diabetes. For more complete therapeutic use data on chlorpromazine (8 types), please visit the HSDB record page. Drug Warnings …Studies…indicate…an increased incidence of difficulties in patients taking oral hypoglycemic agents. Ventricular tachycardia and ventricular fibrillation often occur in the early stages of myocardial infarction. Sulfonylureas: Sulfonylureas should be used with caution in patients with renal or hepatic impairment. Veterinarian: Avoid use in pregnant animals. Veterinarian: Sulfonylureas are of very limited efficacy in the treatment of canine diabetes, with only a very small number of mild cases showing improvement. /Sulfonylureas for Lowering Blood Glucose/ For more complete data on chlorpromazine (18 in total), please visit the HSDB records page. Pharmacodynamics Chlorpromazine is a second-generation sulfonylurea used in combination with diet therapy to lower blood glucose levels in patients with type 2 diabetes. Chlorpromazine is twice as potent as glipizide, another second-generation sulfonylurea. |
| Molecular Formula |
C10H13CLN2O3S
|
|---|---|
| Molecular Weight |
276.74
|
| Exact Mass |
276.033
|
| CAS # |
94-20-2
|
| PubChem CID |
2727
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
433.5±47.0 °C at 760 mmHg
|
| Melting Point |
128 °C
|
| Flash Point |
216.0±29.3 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.585
|
| LogP |
2.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
17
|
| Complexity |
345
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
RKWGIWYCVPQPMF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)
|
| Chemical Name |
1-(4-chlorophenyl)sulfonyl-3-propylurea
|
| Synonyms |
Diabinese; Chloropropamide; Chlorpropamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~361.35 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6135 mL | 18.0675 mL | 36.1350 mL | |
| 5 mM | 0.7227 mL | 3.6135 mL | 7.2270 mL | |
| 10 mM | 0.3614 mL | 1.8068 mL | 3.6135 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.